Call for Help from WA Medical Cannabis Access Points

Estimating the medical cannabis market for the WSLCB:

Left to right: CASP Board member Don E. Wirtschafter, esq; Don Skakie; Reverend Jeff Church; NORML President Kevin Oliver; Medical Cannabis Producer Shawn DeNae; and Dr. Corva. Panel from 2014 Seattle Hempfest Hemposium.

Photo by Steve Hyde

by Dr. Dominic Corva, Executive Director

CASP requests assistance from all Washington State Medical Cannabis Access Points! We have been contracted by BOTEC to help develop and administer an anonymous, 10-question survey to this part of the medical cannabis industry. The surveys will be aggregated and run through a BOTEC-developed econometric model to estimate the size of Washington’s medical marijuana retail market. The results will be presented to the Washington State Liquor Control Board, who will then use the results to make big decisions about the new 502 retail window and the issuance of medical “endorsements.”

In addition to being anonymous, a further step has been taken to insulate the information providers from identification. We have received a letter from the WSLCB stating that they will not have access to the raw data. It is available here: BOTEC – Letter on behalf of LCB – FINAL.

In the interest of transparency, I am fully aware that our information network is being used in exchange for money. I have two observations about that: our network tends toward the collaborative side, and it’s tough to ask people for money just because. The value of our community’s interest in knowledge-based policy makes this a public service, not just a policymaker service.

This contract breaks new ground for CASP, and we are humbled to be invited to steward the production of useful knowledge. The better informed policy is, the better the policy is. We make no grand claims about this knowledge: it will have to be refined and undoubtedly will be used for many purposes.  We only claim that it will be better for your participation.

If you are an access point owner in Washington State, please contact Dr. Corva at dominic@caspcenter.org to receive the survey and answer any questions.

Thank you very much for your time and consideration. We hope to hear from you soon! We have a small window of time to do this, as the LCB will need processed results in just a few weeks.

 

Brazil: To Be or CBD? Not the Question.

Executive Director’s Note: CASP is proud to share authentic journalism from our friend Ras Stephen Charles Flohr, reporting from where he lives in Sao Paulo, Brasil, on the way new CBD-specific politics intersect with inequality. It is part of an ongoing interest CASP has in educating the public about the realities of Cannabidial as it relates on the one hand to the whole plant, and therefore herbal medicine; and as it relates to the politics and economics of global cannabis prohibition — Dominic Corva, September 2015

004

Photo by Stephen Charles Flohr

By Stephen Charles Flohr

July 5, 2015 – Sao Paulo, Brasil

Football, Carnival, beach life and lots of beautiful women. Sounds like fun, right? Yet in the country where cachaca (national spirit)  is the bloodstream fueling all of its major cultural and economic norms of engagement, burning a spliff is a surprisingly tense and taboo affair.  One would think that with all of the natural beauty abounding that Brazil would have a more sensitive, relaxed and tolerant attitude regarding the herb.  But this is not the case.  Ganja is viewed and treated as a social ill which perpetuates the nation’s greatest plague, drug trafficking, and is inextricably linked to the violence which devastates primarily the poor, yet undoubtedly shapes and haunts the lives of every citizen. These are the front lines of the “drug war” and they’re ugly.  And so the weed is ugly, most often in the form of a pressed and condensed brick, desiccated and sometimes moldy, more often than not from Paraguay. The aftertaste has a distinctively chemical hue.  And if you want some, you must head to the spot in a local favela (ghetto/slum) and deal with armed youth whose livelihood is the drug game, and be prepared to deal with the militarized and notoriously heavy-handed police force who are always in hot pursuit of potential slingers.  Even speaking about cannabis is a risky enterprise.  Brazil has a history of arresting entertainers on the charge of “drug apologetics”, a crime punishable by 1-3 years in prison if convicted. The most recent incident took place during a show in June where “Cert”, vocalist for the band ConeCrew, known for their progressive cannabical posture, was arrested by police on stage as he performed.  And if you are thinking about wearing a cap or shirt brandishing the leaf, be forewarned.  Police routinely arrest youth for displaying images of marijuana (maconha) under the same auspices of drug apologetics.

However, with the undeniable global, medicinal and economic potential of the herb, especially in light of recent medicinal and legislative milestones forged in the U.S.A., it is proving too difficult and costly for Brazil to remain so tragically aloof from science and common sense.  Users of marijuana and patients in particular are demanding a change in federal policy which currently criminalizes even the most minor possession and often results in the prosecution of mere users/growers as if they were traffickers. But the tide is turning, and with neighboring Uruguay on “all systems blow”, the stage is being set for a radical cultural shift that could be at least part of the solution to  Brazil’s pandemic violence and abject poverty, not to mention a bolstering influence on  its’ precarious health care plight.  

CBD Legislation and Access

Earlier in 2015, the Brazilian federal regulatory organ responsible for the importation/exportation of internationally sanctioned drugs, ANVISA, reclassified the isolated cannabinoid CBD, a  medicinal derivative found in the cannabis plant, and liberated its importation in strictly specified cases of chronic epilepsy.  The decision came after a long push from several families who pursued successful treatment of their children’s deadly epileptic conditions using CBD oil. A documentary entitled “Illegal” by journalist Tarso Araújo, takes a deep look into the challenges these families confronted  and brought national attention to the issue and the possibility of “medicinal cannabis”.  But cannabis still remains illegal under federal law and it is still therefore illegal to grow it and thereby impossible to produce a legal CBD extraction domestically.  And so critics are lauding this supposed “advancement” in cannabis policy as bittersweet.  They argue that the CBD Import-Only legislation, while an absolute victory for families and children in immediate need of medicine, is also a major victory for foreign markets, mainly in the USA, who are all too eager at sinking their claws into the emerging market that it proliferates.  

And so who is really getting access to treatment with CBD?  As the ANVISA ruling currently stipulates, only patients with life-threatening epileptic conditions are permitted access to CBD and that only under stringent medical and bureaucratic exigencies.  And the cost?  A monthly supply for a patient at a dosage of one gram of CBD oil per day is a whopping $4,800 reais (about $1,600 USD).  To give you an idea of just how expensive that is, know that the minimum wage in Brazil is $788 reais (about $260 USD).  For this reason, it is obvious that the remedy is not accessible to a large percentage of eligible patients. Add the fact that the efficacy of CBD-only treatments is questionable when factoring in the unique specificities of different illnesses and when compared to whole plant applications, and the margin of those benefiting from this legislation becomes even slimmer. But that hasn’t stopped  HempMeds , subsidiary of Medical Marijuana Inc,  from cashing in on the situation and  using their success in Brazil as a platform to build support and infrastructure in American states where medicinal marijuana is in its fledgling state.  When it comes to hemp-based products in Brazil, HempMeds is basically the only show in town.  Its quasi-monopolic vicegrip on the CBD niche market coupled with its’s dubious corporate history has raised eyebrows and tempers amongst patients and activists alike.  Basing her argument on the findings of Israeli researcher Ruth Galilly which present compelling evidence for the superior efficiacy of whole-plant remedies, Susan Witte of the Multidisciplinary Association for the Study of Medicinal Marijuana laments, “It doesn’t make sense, therefore, to grant cannabidiol monopoly status to corporations that intend on selling these remedies at the highest possible profit, if that means offering a product which is less effective than the compound’s original source in nature”.  On the other end of the spectrum, Dr. José Alexandre Crippa, a stuanch advocate of CBD-only intervention therapies, currently holds several patents for a synthetic isolated form of CBD and plans on working in tandem with the pharmaceutical industry in making it available to the public as a domestically viable and more affordable option. As if CBD-only reform didn’t already completely miss the mark, I can’t help but cringe at the spectre of a  national “synthetic CBD-only” debate.

Fighting Back

In Brazil, there exists a politically strong and religiously motivated bloc of elites who assume a “ProLife = AntiCannabis” agenda and view the stoner (maconheiro) as one of the greatest threats to not only the peace and stability of society as a whole but also to the integrity of the family.  They most often have no qualms with current alcohol legislation yet wage their intolerant crusades against a plant based on their adherence to a myth of religious and racial superiority.  And so the masses aren’t holding their breath waiting for a political miracle to take place, especially those patients who are already finding it difficult to breathe. They’ve decided, instead, to take matters into their own hands.  Affirming their human rights and deciding that  medical necessity trumps the obligation to abide by unjust laws, patients of all types and their caretakers have taken to growing their own cannabis and preparing their own medicinal extractions.  

Joao is a 47 year old engineer from Sao Paulo. He suffers from rheumatoid arthritis and diabetes and is both patient activist and participant in the city’s  annual “Marijuana March. “We’re tired of supporting drug terrorism and risking ourselves for shit product time and time again”, he says.  “We’re not all epileptic and rich.  We have MS, Diabetes, Parkinson’s, Cancer, AIDS and God knows what else. We all have a right to treatment too.  Cannabis grows freely and if you take care of it, it can take care of you. Simple.”  This sentiment has proved to be the fertile soil from which a number of underground patient-caretaker initiatives have spread across several of Brazil’s major cities, especially Sao Paulo and Rio de Janeiro.  Joao comments about how a friend of his who has MS benefits from the network of stealth CBD providers. “It just shows up in his mailbox. He has no idea who makes it but he is grateful that they do. And he doesn’t pay a thing.”

“There is absolutely no commercial gain in this type of practice, its an issue of solidarity, its about helping people” affirms a young member of one of these clandestine groups in a report by the Brazilian news source Globo.  “Which is a greater crime, trafficking for love or letting someone die from 20-30 convulsions a day?”, he adds. The report brings to light several cases of financially strapped families in Rio who are desperate to provide CBD-oil to their gravely ill children and therefore seek out artisanal extractions performed in the homes of a brave bunch of outlaw pharmacists.  

Criminal Attorney Paulo Freitas confirms the severity of the legal risks involved:

“Anyone who plants ‘ganja’ is subject to the criminal laws of drug trafficking; it is an activity considered equal to that of trafficking. Yet beyond that you also run the risk of committing a more serious offense, namely that of fabricating and providing, even if the intent and practice of distribution is free of charge, a medicinal product without registration at ANVISA, punishable by a 10 year minimum sentence in prison which is double the minimum for trafficking.”

But love must sometimes flout the law. “Illegal, in my opinion, is the way that things are, to deny me the right to give a better condition of life for my daughter. This is what I think is illegal”, confirms Fabio, father of Clarian, who was born with Dravet Syndrome.  Fabio sought out homemade CBD- extraction for his daughter as the only feasible option as he and his family faced an $8,000 reais  (nearly $3000 USD) monthly expense in the procurement of enough medicine through existing legal channels.

Pushing the Envelope

It is evident from the developments in Brazil that people are willing to seek and provide wellness and healing at great personal risk.   Ignoring the fact that CBD has its origin in the cannabis plant and declaring the former as legal and the latter as not points to a deeper, hypocritical confusion.  Its like saying the red coloring of a strawberry is good but the berry itself is bad.  Astute activists remain adamant in their pursuit of whole plant liberation. Whole plant remedies with various CBD:THC proportions hold promising potential for a gamut of maladies.  But for any meaningful research to be conducted, domestic cultivation of the plant is a necessity.

It is frustrating that this so-called ‘baby step’ was wrought in almost complete dismissal of logic and panders supremely to a foreign profiteer.  This is a service and medical necessity which Brazil could easily carry out on its own on a much larger and efficient scale without having to resort to importation. The law also confirms the fact that Science, or at least the fraction of it which the government deems fit for public awareness, is an exclusive privilege afforded to the economic elite. But Brazil doesn’t seem to have a problem with conspicuous capitalism and I can think of few places which exhibit such a glaring disparity between the haves and the have-nots. And so even if you do happen to help people see cannabis as a medicine and not a plague, you will then have the challenge of its commercialization.  “Ok, so cannabis is good now how do we make the most money off of it.”  Health is a commodity and until ‘the haves’ devise a scheme to control its sale and maintain an underclass consumer base, the senate isn’t going to budge on real cannabis talk. And yet the grassroots continue to bloom in the shadows of obscurity, healing the sick and waking the sleepers, risking it all because, well, we are all worth it!

[VIDEO] Kevin Jodrey on the emergence of Cannabidiol (CBD)

wonderland_instagram
Photo source: @Wonderlandnursery (Instagram)

For Ethnography into the Human-Cannabis Relationship is a collaboration between filmmaker Steve Hyde and social scientist Dominic Corva Ph.D. Ethnographic interviews differ from other kinds of interviews because an ethnographic approach seeks to shine a light on the ways that individual experiences reflect collective ones. This episode is an interview with Kevin Jodrey at the Seattle Hemp Fest August 17th 2015.

Kevin co-founded The Ganjier and has been a commercial propagator of cannabis for decades, running his own operations and offering consulting services. He considers himself a steward of the plant and has long had a fascination with it. As an internationally respected cannabis expert and easily the most well-known Humboldt cultivator, he has spoken at universities, been a judge at the Emerald Cup, and consulted with TV networks on cannabis-related programming. Featured in the New York Times, the Washington Post, countless other articles, books, and radio shows, he is at the epicenter of the modern cannabis movement. He owns Wonderland Nursery in Humboldt County, CA .
source: www.thegangier.com

https://www.youtube.com/watch?v=u0nsQBFgkiA

The Original Terpestival™ and Terpene Crown™

The Original Terpestival™ and Terpene Crown™

By Dr. Michelle Sexton

The First Original Terpestival™ and Terpene Crown™ was held in Seattle on July 23rd to a sell-out crowd, who came to celebrate the aroma and properties of the terpenes. Dr. Ethan Russo, an internationally recognized Cannabis historian, Board-certified neurologist, psychopharmacology researcher and Medical Director for Phytecs from Vashon Island, was the keynote speaker. Dr. Russo detailed the terpenoid class of compounds in cannabis and reported some of what is known about biological activity of these compounds. The Center for the Study of Cannabis and Social Policy (CASP) reached a milestone in this successful fund-raising event. CASP collects and produces information about cannabis policy and markets in the context of state-level experiments in democracy directly affected by Legal Cannabis laws, rules, and regulations.

The event kicked off with a VIP party and food-truck event along with with sponsor booths for festival-goers to peruse. CASP also hosted the “Aroma Bar”, a place to tickle and train the nose in recognizing different terpenes common to Cannabis and other aromatic plants such as Hops, Rosemary, Sweet Orange and Black Pepper. Following Dr. Russo’s address, there was a panel focused on discussion of various methods of extraction, genetics and genetic diversity and medical aspects of the whole plant. Panel members were Reverend Jeff Church, The Ganjier, Kevin Jodrey, and Dr. Michelle Sexton, Executive Medical Research Director at CASP.

The Terpene Crown was publicized to offer 6 awards in each category for flower and solventless concentrates (CO2 extraction was accepted). Terepene analysis was performed by The Werc Shop, (using GC/FID) as an in-kind donation to CASP for the event. The Werc Shop quantified 15 terpenoids and results were reported as a percent of total weight of the sample. Winners were selected by a Judging Panel, which was blinded to the entrants, as were the laboratory and individual Judges that provided the “subjective” information on the entries. The winners were selected based on a weighted average of the subjective results and the quantitative data. The aggregate results along, with the winners in each category, are in the graphs below for Flower, Extracts and Total Terpenes for Flower and Extracts. The graphs contain the name of the entrant as well as the varietal name of the winner.

In an inadvertent misunderstanding on the day of the awards ceremony, we mistakenly “disqualified” two entries in the Extracts category. Our deep regrets to Reverend Jeff Church of Thinc Pure, whose entry of a Sour Diesel CO2 extract is obviously in a mystical and alchemically distinguished category, of its’ own. It was a clear outlier, as the terpenoid content of the 15 terpenoids measured was 38.4%. This extract was also an outlier for limonene content measuring 4% limonene. The second entry, an “anonymous” extract, was also disqualified from the standard categories but then awarded the second place “Outlier Award” for total tcontent of the 15 terpenoids quantified at 22.4% and β-myrcene content of 6.6%.

The basic hypothesis in the design of the analysis and survey was that particular ratios of terpenoids or high/low levels of individual terpenoids might correlate with the felt experience reported by the judges. However, in comparing the quantitative data to the judges’ subjective experience, there was no correlation between what the judges rated as the “Most sedating” or “Most Stimulating” entries and myrcene content, myrcene:pinene ratio, pinene content and pinene/myrcene ratio. In contrast, there was a robust correlation between pinene content and “piney” taste by the judges, and a loose correlation between limonene content and “lemony” taste.

Judge’s Award for the “Most stimulating” was for Cascadia Kush flower, grown by Hesperides’ Kevin Kelly, and Canna Tsu raw CO2 extract by Mike West of Green Lion Farms. Cascadia Kush ranked second out of the 19 flower entries for total pinene content (α + β Pinene). Pinene has been reported to act as an inhibitor for the break-down of acetylcholine, a neurotransmitter, which may explain the cognitive and physically stimulating effects that some users report with strains high in pinene. Canna Tsu extract had a relatively low level of pinene and pinene: myrcene ratio compared to other extracts.

The Judge’s award for “Most Sedating” was a sweep by Shawn DeNae of Washington Bud Company for Harlequin flower and “Entourage” oil, using an apparently a novel CO2 extraction protocol by Eden Labs.

These results support the idea that the “entourage” effect, attributed to terpenoids, on the cannabinoid experience is not amenable to simplistic or reductionist science (Surprised? We are not!). It is possible that our “sample size” of judges was not large enough to lead to significant conclusions. Nevertheless, it seems clear that while analytical results may say: “this one is really high in pinene” (for instance), the judges’ ability to perceive this was variable, as expected. In agreement with most published scientific data, the terpene content (based on the 15 compounds analyzed) was as expected in flower, < typically 3% from indoor-grown flower, and with an average of 1.4%. The contribution of the terpenoids to the whole plant experience may be “unquantifiable” from the user perspective, and yet this class of compounds is an critical element to both the medicinal and experiential effects. While we at CASP were celebrating the aroma/terpenes of cannabis, on the same day, medical cannabis in Washington State became confined to “closed containers” in retail outlets. In these outlets, medical and adult users alike will no longer be able to select their desired products by following their noses! This is such a strange and unreasonable policy, and we hope to be able to continue influence such public policy at CASP by providing the science and research on which such policies can be refined. 001

002

003

004

There were many who worked tirelessly to birth this CASP fundraiser, including our two event coordinators, Wendy Maguire of WLM and Co LLC, and Lara Kaminski. Former CASP Board member Joy Beckerman went well beyond the call of duty and brought her unrivaled expertise in event-planning and complete oversight. We are extremely grateful to all of our sponsors. At the Diterpene level: Eden Labs, ThincPure, the CPC, The Wercshop; at the Sesquiterpene Level: Northwest Cannabis Classic; Cannacon, DB3 Inc, Terpinator, Northwest Leaf, the CCSE and Wonderland; at the Monoterpene Level: Seniors MMJ Network, Cannabis Basics, TDCANN and Assoc., Blue Crow Organics, Garden Extracts, True North, Bud Nation Seattle, NW Patient Resource Center, Gleam law and Washington Bud Co; and the in-kind donations from Lyon’s Cases, Dockside, GES and The Herbalist.

We graciously acknowledge the NORML women’s Alliance, the Ganjier, and the CASP Board Members who put many hours of work in behind the scenes. Our deepest gratitude for all who participated, donated, bought tickets, entered the contest, and helped to promote the event in social networks. We are greatly touched by the support for what we are doing at CASP and for our ongoing research. We hope that this is the beginning of a trend for engaging the community in helping to perpetuate the work that we are so passionate about: collecting and producing information. If you did not get to support CASP by attending or participating in the event, we invite you to donate to our ongoing work, please visit our website!

Mission, Audiences, Standpoint

Cannabidiol: a conversation about the emergence of CBD

INTRODUCTION
by Steve Hyde
Research Associate and Communications Director

For Ethnography into the Human Cannabis Relationship is a collaboration between filmmaker Steve Hyde and social scientist Dominic Corva Ph.D. Ethnographic interviews differ from other kinds of interviews because an ethnographic approach seeks to shine a light on the ways that individual experiences often reflect collective ones.

The human geography story we develop here is a structural story. It’s a geographic tale about the emergence of CBD genetics in the American West. This episode of For Ethnography into the Human Cannabis Relationship is based on an hour-long interview with Christopher Larson, a grower who is a producing member of the TeaHouse Collective known for its emphasis on CBD rich genetics. As an agriculturalist, he is dedicated to growing only organic, sustainable sun-grown cannabis. His creative partnership with Lawrence Ringo produced Lost Coast Botanicals, which, as the website suggests, is source for “CBD and Sustainably Grown Medicinals”

Here we present a story that offers a glimpse into the lives of cannabis growers in Northern California. It’s a glimpse into the lives of people who grow plants collectively to produce medicine, distribute it and gather observational data concerning its efficacy for patients. The discoveries made by experimental cannabis growers have great significance for medicine and science. These creative growers make new discoveries all the time – They reach out to lab scientists for mentorship and guidance in science practices and they experiment in a variety of ways that often produce astonishing results. And the results of the experimentation has been a wide range of useful new treatments for a variety of medical conditions.

This story is about the growers who recognized they had discovered something unique in cannabidiol (CBD). The plants were smaller and didn’t produce as much and the cannabis culture didn’t cultivate it because CBD flowers developed a reputation as something that doesn’t get anybody “high”. This group of growers realized they were growing something different. Maybe it’s in the plants terpenes – they wondered. Lab results of plant material suggested yes, that cannabidiol-rich cannabis does appear to have more myrcene and linalool. Maybe cannabidiol has something to do with that? That question brings us to July, 2015.

Dedicated to the memory of Lawrence Ringo. (featured in the photograph below)

ringo

Summary

This video and its transcription were developed for the purposes of higher eduction. This work is a source of primary data. Typos, mistakes and video recording errors exist. Please contact the Center for the Study of Cannabis and Social Policy to report errors or for a free copy of the video and transcript.

Center for the Study of Cannabis and Social Policy (CASP) is a not-for-profit research think tank dedicated to learning lessons for legal landscapes and studying the human-cannabis relationship.

http://https://www.youtube.com/watch?t=134&v=TVZwT3U43aQ

For Ethnography into the Human Cannabis Relationship
Dominic Corva PhD Interviews Christopher Larson from Lost Coast Botanicals and the Tea House Collective in Humboldt County California.

Interview by Dominic Corva PhD
Video by Steve Hyde

*** Please be advised there are text transcription errors present in this text. (07.18.2015) The dashed line indicates untranscribed speech “_____”. Square brackets [ . . .] indicate subjective translation. ***

AUDIO START (TRT 60 Minutes)

Dr. Corva: So, obviously, Christopher you’ve seen me talk to lots of people, I’ve talked to you already, but for this one, I just want to make sure I remind us about it because sometimes I’ll forget – that the structural story that we want to get at – is the emergence of CBD genetics in United States, in California in particular. And the ethnographic way to get at it is to talk to the people who were in the middle of it and who were, you know, connected to it and it’s less about, okay, this happened then, but more about this is how my life developed in conjunction with it. So, there’s aspects to it that are helpful such as, you know, trying to remember dates as specifically as possible, you know, but general timeframes of the year, let’s just say that the unit is year, if possible, but this also of course besides the CBD genetics getting here, I’d also like to hear the story of how you met Ringo and how that partnership started and to get at that story and through the lens of the social relationships that made it happen.

Christopher: Yeah, that was really my introduction to Lawrence. It was through Cath, you know, his partner, Cath Hart. Cath did festivals for years, you know, music festivals and that’s what we did too. I mean as well with our ____ and our import things and our tools and so forth at music festivals. So, we knew Cath really well, you know, always neighbors and always good energy – a great artist who did beautiful work, I really liked the work a lot and she would talk about her partner, you know, but I thought was that just a business partner? or was that a romantic partner or something? I didn’t really know, you know. And then it turned out to be Lawrence, _____ and so I think it was at the Emerald Cup, one of the Emerald cups in 2009 I guess it was.

Dr. Corva: So, in Laytonville?

Christopher: It must have been yeah because that was ____ at the Mateel or it might have been actually ____ one of the Hempfest at Mateel in 2009, I think that’s what it actually was when Lawrence had started selling his seed and he hadn’t been doing that that long and the thing was it was Cath that really got him into the whole idea of… oh, you need to organize your product to make ____ because she had great experience in doing shows too, I mean selling to the public essentially and he wouldn’t have been able to do it otherwise. He did just, you know, he had an idea and he wanted to be a rock star that was his big thing. He was a hell of musician and so he had a sense of showmanship and being in public, he was comfortable with that, but the rest not a clue. So, I mean they were getting their first little packets of seeds together and so forth and in his first wave of offering to the public. I mean we had all traded seeds with each other for years, you know, and the deal was you’d sell seeds if you had something good and you had a good name for it. [Price was] a buck to three bucks for seeds. That was the going rate for a long time and [for three] it was like people would raise eyebrows a little bit, but if [the seeds] were really good, you know, that was okay. The next step of course was sexed plants, you know, and that was_____ price would vary if you had a nice, healthy sexed plant, you know, that was what was going on, there wasn’t a lot of cloning at that point, you know.

Dr. Corva: Even in 2009?

Christopher: There was cloning going on, but no, not in our neighborhood, you know. People were still doing a good job of stabilizing seed, you know, and so that was what you looked for, you know, there was a hardiness to it and there was a lot of stuff. It was very much associated with indoor – the clones were. So to do that, you know. So anyway, here’s Lawrence and he’s, you know, very much associated with outdoor and growing in the sun and so forth, but he had been buying fancy seeds from Holland and then working that into his breeding program and being bound ____ the seed he was getting from Holland because he felt like they were misrepresenting. you know [he thought] it was all crap. that [the seed] wasn’t what it was supposed to be and so forth and so on, which was the case. I mean it was all over the map and he had the seeds, so great, you know. I wasn’t really ____ He didn’t offer any strains of CBD at that point, but he had identified CBD at that point. It was actually the Sour Tsunami, yeah, Swiss Gold came later into the thing and so he had identified the Sour Tsunami, which was great. He could ____ and he picked up some clones of Cannatonic and Harlequin both. And then he began to breed some seed on it, but that wasn’t what he was supposed to have there. He was supposed to have these other things, Granny Derkel we called it, it was Purple Urkle, you know, the big purples that were so popular, there was a range of them that… what’s his name, cashed in on. It was the Grand Daddy Purple. And this was Lawrence’s little cross. Well, it was great except it turned out it was really high… full of CBD quite high, I mean, you know…

Dr. Corva: The Purple Urkle was?

Christopher: Well, the seed. I was buying seed for them and I grew the seed out and I was expecting to have this really nice stable, you know, ____ product and it turned out to be pretty high in CBD, it _____ with very high CBD and then I got intrigued about the whole thing like, well, how much [CBD] is really in there and there weren’t any labs available at that point. There was Samantha Miller down in Santa Rosa so that was great because there was some way to [test] what was going on. In the meantime, that was the year the same seed she had done that study that showed up in O’Shaughnessy’s comparing seven different phenotypes types out of the ____ based on the Sour Tsunami cross with this and that and [published] a nice chart and so – here was Lawrence – on the one hand how to pack and market and sit there at the table and do things and on the other hand how to actually quantify his seed breeding program, you know, and it was just the beginning [when we] came together and we were just about to form Tea House at that point. So, anyway, [that is how we] developed an interest in breeding because I had been doing [seed] stabilizing.

Dr. Corva: Quick question, so the Purple Urkle was crossed to Sour Tsunami that was then…?

Christopher: Nobody knows whether it was crossed or not. It was all serendipitous. [Pollen was blowing] all over the place, but that was the primary CBD donor probably at that point and any cross to bunch of AC/DC with the Sour Tsunami pollen that he was able to get. That [was the great feat]that he did – was to create male pollen – high CBD so that he could add that to the available clones, you know that was the deal and then also Bill Courtney took an interest and he brought us up a bunch of the Cannatonic clones from Spain that were seeds that he cracked and there was a whole range and it was great, he handed them out there, he handed out a bunch to HPRC – basically and here in Arcata and I got some from them, Aaron had to move his scene, he was freaked out, he gave a bunch of mismarked Cannatonics. Now, the neat story about that is what we call C6 now was marked C6 when I got that from strain from Aaron and it was a 1:1 strain, which is really nice desirable strain quite high overall and I call it C6 because that is what I knew it as, but then I heard down from the workshop, you know, Mark said, no, no, it’s not C6, it must be C18 or C16, you know, it probably was at one time, but unfortunately we kind of notoriously got to call C6 and I feel kind of directly responsible, but that’s what we knew and there was a lot of mixed up stuff, but anyway we started breeding after that and began to, you know, get to understand what we had and you know – section it off and be careful and there were always these little things that we have, but you know we still got mixed up, serendipitous kind of you know cross-pollination that nobody was expecting like Granny Urkle that sort of thing, you know, but out of that so I just — we developed more and more relationship anyway around the breeding and then around the extraction because at that point the next step was okay, how do you quantify, how do you get into some measurable amount and Lawrence was doing ethanol extraction at that time and so it was great he had, it was like rice cooker just basically, which were really set too hot and so the earlier ones were 120 degrees, which is just a little too hot to really control it, but that’s what we had to work with and then it was like, oh, bring it down to 115 degrees is a little slower, but it’s a lot more, you know, safe and then even 110 it will work and so gradually refining that process.

Dr. Corva: What’s not safe about it in higher temperatures?

Christopher: It tends to scorch, it will scorch on the bottom and before you know it, right at the end it will finish, you know, you’ve got a black melted mess, you know, decarboxylated – so that was interesting and so around these various things, you know, we didn’t really, then we began to get real scientific equipment and some basic to organic chemistry practice and understand it, that was pretty cool, but that was quite a bit later so that’s where I knew Lawrence from. It was let’s go in the kitchen and make stuff and that was pretty cool and out of that the thing was, of course, then we had to learn what is CBD, what can it do, you know, what are its properties, you know.

Dr. Corva: Let me ask you real quick and remember that as a book mark – what can it do and so forth, but did you have a little more experience than him at extracting or did you guys both kind of like?

Christopher: We started from the same point of view. I moved down to doing the CO2 and kind of encouraged that. He was still very much into the growing aspect.

Dr. Corva: There seemed to be a partnership.

Christopher: He wanted to be that, yeah, but that’s why it worked so well. I mean we had different areas you could bring together and it just worked really great, you know, and you know he didn’t have moral aversion to BHO but it was clear that this was not, he couldn’t do this in a healthy way and there was such out of, everybody is being so careless and so just greedy and lying basically about, oh, we’ve got completely clean BHO, you know, and really lying about so many things, you know, that was the whole industry, you know, and just a tissue of lies, you know, and that would make him indignant — I loved that about him, he would get indignant about the bull shit, you know, and we had that in common, you know, we kind of wanted to rangle toward what’s really true here, you know, what is really true, you know, and I mean if it wasn’t really pointed out, he would exaggerate things, but once he came to see and what was true, he accepted truth and hold to that, you know, what I mean, it’s like if nobody said anything different, then he didn’t know any better then it’s wonderful – it cure cancer and everything – but once it was cleared and that was not necessarily the case, yeah, he’d endorse that and that was good. So, basically, he was just a really kind of sweet and honorable person, you know, and he was so sweet underneath all the desire to be a rock star and desire for ego gratification and all that stuff, you know, sweet guy, you know, and he had had exposed all the usual crap that all of us get, you know, and got those imprints and he was trying to get over it, you know, and trying to get over being a male chauvinist pig, you know, essentially, (laughs) but he recognizing that he had to do that and willing to make the changes, you know. It was all to brief. And then when he got cancer, it was like we really just couldn’t believe it. We both just looked at each other like what the hell, you know what I mean, and that was his reaction and really before he could start, you know, applying everything possible to treat it, he was dead you know. It took four months from the time that he was diagnosed. We were in LA, actually made a trip down to the workshop, bringing CBD material down there to not well, we would bring some tests stuff to Mark but we were also, another story, but…

Dr. Corva: Yeah. So, that would have been right after the Emerald Cup actually that he was diagnosed, right?

Christopher: It was pretty much after the Emerald Cup. We did that. We recorded a radio show with Kerry Reynolds and that was aired while we here in LA and we listened to it down there because we couldn’t be in the studio that Sunday to do it and he was coughing, he had this horrible hack, it’s like, stay away from me, sharing a room…made me sick, you know. He’s like I don’t know what’s the matter; man I think I got the flu. Well, then a week later, so that’s how I can date it because whatever that date was that show aired that’s when we figured this up and a week later he got an oncologist and said you had to come to see me and two weeks later he was diagnosed with serious lung cancer, stage four – metastasized all through his back, it was really bad.

Dr. Corva: I did visit him in Rico when he was doing the outpatient thing and I did – shortly before he passed – do an exit interview, but that was back at his place with Cath.

Christopher: At least he got to go home at the end run, yeah, so yeah I was there as a hospice volunteer with him and the day before he died and it was coming really fast, that was just…. yeah, he was so bewildered by it, you know, he never got over being so bewildered by it.

Dr. Corva: Yeah, no kidding, yeah. Well, I mean, it’s such a compressed amount of time, I mean for all of us I think in the last six years – no matter what age we started at has been totally, you know, everything has changed, so much has changed.

Christopher: So much did change. It was right at the beginning of the whole idea of quantified medicine and what is in there and what’s going on and at that point it was still, the big race was to see how we can get the THC and that — not that that’s totally blamable, but it’s clear that you know even in the, well, the next thing we liked told Cath was look at this stuff, it won the Emerald Cup where they actually have judges that judge, okay, and it’s different than not, you know, other things and so this is not the high ones, it’s not the high THCs that are appealing ones there. And that’s not the case in the community, I mean for the most part the things that people love and want to come back for but they’re not always like that, but then that was just about pre-dab so that’s all turned into another thing.

Dr. Corva: So much has changed. So, in terms of your education and knowledge about CBD, at what point did you get your first quantified test?

Christopher: That would have been – I mean – in 2010 from Halent Labs as well as mine of course actually went through Halent Lab there and then through an account that Lawrence had. And then also through Samantha, I think I’ve got some ones from Samantha.

Dr. Corva: So, Ringo basically had…had been getting other tests, I’m trying to figure out like, you know, the awareness of CBD, it was there, it was out, the project CBD I think had already been going on a couple of years at that point.

Christopher: Yeah. I think Martin started, yeah, probably just officially started project CBD I think in maybe 2010.

Dr. Corva: So, 2010 and might not happened yet. There seemed to remember like O’Shaugnessey’s was looking at it.

Christopher: Yeah – O’Shaugnessey’s was looking at it.

Dr. Corva: And that would have been obviously like why Martin would know to start project CBD, but I’m trying to wrap my head around the idea of actually like being aware of CBD and trying to brief before you’re actually even getting tests that indicate that you got it.

Christopher: Well, I didn’t really come to it that way. So, I’m saying, well, I guess it basically I did because I had this material that seemed to be really different, you know, what’s the deal, it’s really tasty. It actually turned out to be quite high linalool and myrcene. It was myrcene high and they found this in the Sour Tsunami and it did give this very gratifying feeling, from the neck you could get this physical effect as though your neck was kind of, and shoulders were beginning to just relax and soften, that was the effect it had for me – and I did want to know what was the deal with it so I found it to be really interesting, but you know it’s a hard thing to quantify. I mean, once we understood that was a big component of it, that I was really interested – and then we could begin to compare, you know, what it was like these different ones, but there was nothing about just saying this is a plant and I recognize it before I was told what it was. I didn’t really know what it was. I knew it didn’t get you high the same way. So that much was clear.

Dr. Corva: It strikes me that, you know, the effects that you’re observing saying this plant is different, although of course like the CBD part of it is very important, but also as you mentioned terpenes is that like those effects are coming from not just obviously the CBD, but the entourage effect and so…like.

Christopher: So, some of those plants tend to have those profiles in them, you know, until we’ve seen them in the CBD in particular, I don’t know of any CBD plants that are disassociated from that particular list of terpenes, they may be around, but I don’t grow them, you know, I mean I don’t have those. I haven’t seen them. Even the crosses with, you know, the big leaf Swiss Gold in a step, which we thought we were on to a whole another kind of thing, we called it Indica, you know, it seems like it was like an Indica(y) kind of plant, but it had actually had those same terpenes in it. So, it wasn’t that different.

Dr. Corva: Where did the Swiss Gold come from? Can you elaborate a little bit more on that?

Christopher: The Swiss Gold, that was a bought seed that he had ordered from such place, I presume it was Dutch I mean that’s where all the seed companies were that he worked with and then the other was by way of Canada, you know, there’s bunch of Canadian bunch –Mark Emery is who I ordered stuff from. But Mark never marketed anything as CBD – at least that I was aware of – when he started that, so I am pretty sure that’s where it came from.

Dr. Corva: So, were they marketed as CBD?

Christopher: No, that just turned up. That was the serendipitous discovery and then what was the other one, oh, there was one that was called Oracle that was supposed to be something that it wasn’t and that got to be kind of goofy, Dr. Frankel got all excited about the Oracle, but it was just kind of a feeble AC/DC, which essentially is Cannatonic, so much of it just came out of that first 18 seeds of Cannatonic, but you know the thing is everybody had these memories of the old Oaxacan and the old Michoacan that had the sort of the same feeling to it, you know, that we had not seen in years and years and so there’s no way to go back and know it was high CBD or you know, was that a possibility? But that was the sense, I got. The familiarity went back to something, you know, I mean we all had that experience like, I had this before, but not in years, you know.

Dr. Corva: So, let me back up a moment, 18 Cannatonic seeds, there’s a very precise number; there’s a particular story behind that that I haven’t heard.

Christopher: Oh, you probably have…

Dr. Corva: Maybe, I mean I know from like from Spain, like I know from Spain Cannatonic came. I didn’t…

Christopher: There’s a lab in Berkeley, was one of the earliest genetic, you know, Cannatonic profile labs that Michelle Sexton was associated with. She was actually present when these were done, when these…

Dr. Corva: Right, I remember that. She has told me about that.

Christopher: Yeah, and that’s the place and everything stemmed out of those and then that’s where, that is where, you know, Bill Courtney got his starts from that he got…

Dr. Corva: Is that where the AC/DC line comes from is Bill Courtney?

Christopher: Yeah. Well, I say from theaw seeds.

Dr. Corva: From the seeds, but the Cannatonic seeds Bill Courtney got.

Christopher: I mean physically that’s where I got it from.

Dr. Corva: Right.

Christopher: Now, the backstory about spain and so forth – I don’t really know the details of all of that…that’s where it came from.

Dr. Corva: So, help me out a little bit with AC/DC obviously, you know, most people think of that as distinct from Cannatonic.

Christopher: Well, it appears different, but there’s a whole, like I said, there’s a whole range of these plants that were all part of the same batch as far as I know that expressed themselves differently, and AC/DC is really interesting because it’s got these round stems, it doesn’t have any flat sides on its stem, you know, it’s round, a lot of cannabis has a kind of squared stem or you know corrugated or you know variable, but this is just like a whip and all the little ones and then all the main ones that are tremendously fragile when it’s little and it just breaks if you look at it, but it has some support, it’s fine and then when it dries it’s just super strong. So, that must be some relationship to the hemp plant because you know because hemp has very strong fibers, it was bred for its fibers and certainly it has been that quality but it’s not big, it doesn’t produce a lot.

Dr. Corva: I mean everything you say obviously inspires more thoughts, but this is very interesting because, you know, as I understand with breeding, you know, like one of the things you select for is vigor, and so if you’re selected for vigor, if you don’t know anything else about like AC/DC plant basically like I would assume that that particular type of phenotype would be like first way out the door.

Christopher: Right, if that’s….but see, that’s also to a very high THC content, you know, a lot of the crankier plants are not the ones you choose to grow, they’re not really much fun, oh Jesus, that’s stupid, I mean good lord, you know, and I mean people they’re working on it and they’re more vigorous and better types that nonetheless it would be your first choice from that point of view, from growers point of view, but then so what’s been pointed out is things that are really high out there on the THC spectrum or the CBD spectrum or any other cannabinoid you want to identify are typically going to be a little bizarre in terms of growing patterns. They’re not necessarily most vigorous plants because they’re kind of atypical, you know, anyway and that’s you do see that, you know. So, that was always the tradeoff, the highest numbers what Samantha has taught Lawrence and I learned from Lawrence is the levels stay pretty much the same, the ratios do, but if you just go what we learned from actually growing though is that if you go for the highest number, you won’t necessarily get the best plants, you know, the highest ratio, I should say, okay. And then overall cannabinoids is a big deal too, like you can get these very high ratios, but not very much in the first place. So, take – or select several for a slightly lower ratio and get a much higher overall amount – to me is more desirable but, well, it depends, you know, there’s so many things you’re looking for and I should say, you know, I am basically a self-defense breeder, I stabilized – we keep seed growing forever and we got it really nicely adapted to the coast out there, Train Wreck, you know, that we’re quite happy with you know – seven generations and then we had a big from Douglas – from Doug Fir. For years we’ve had an Afghani – we bred that and bred that, but then we finally lost it, you know, it was just one year we didn’t make seed and that’s the way it is but I was never, you know, I am not, I was never, you know, it was pretty basic, it was not difficult. I never thought it was hard and so it didn’t seem hard, you know, but I realized now we’re pretty fortunate you can take it seriously and breed like crazy and still have trouble getting good results so…

Dr. Corva: Right. In your context, your breeding is being done outdoor, then it’s once a year.

Christopher: That’s right, you know, take forever, you know, six or seven years to get and that was the great acceleration that Lawrence pulled off, but we’re just hitting that too. I mean it wasn’t like it’s been going for a while. Well, you do an indoor crop and then keep going you know so you get it up to two and even three, you know, have one, have two, and have three per year, you know.

Dr. Corva: I mean this is a very good example of like, you know, not being simplistic about like being pro-sun-grown is that, especially for breeding, you know, indoor has an important place.

Christopher: It does, absolutely and we all agreed with that, you know, I mean there is certainly a place for it. It’s not something you just want to ignore. In a larger sense, it’s kind of got the like, any kind of real sense. It was only because it was illegal and needed to be hidden and grown in basements and stuff that that it started, you know, everybody leaned that way. I think that’s got to be pretty thoroughly acknowledged at some point, you know, it doesn’t necessarily produce better material, – the arguments you hear are hilarious.
“I’ll never have anything but indoor” well that’s fine, you know, whatever, with heavy metals and all.

Dr. Corva: Yeah, one of many, many, many urban myths or popular myths about cannabis need to dispelled obviously. So, back to CBD track, I had asked you to sort of bookmark that thought about the effects…and so forth.

Christopher: Well, then, just because we started the cooperative, we made it available for people that was the whole point.

Dr. Corva: Could you talk about it, for obviously I know about it, but…?

Christopher: Yeah. We’ve been a part of a cooperative that was supposed to be basically a farmer to consumer tea house, yeah, collective and that was other people had started that and it was pretty local, sort of by watershed, there were like four watersheds involved essentially and that was the idea to send it down to Berkley to Bay area and distribute it and people would be able to get nice, clean, well grown cannabis, but everybody was just storing in their favorite strain so I think at one point we had 45 different strains or something and it wasn’t really 45 because people were just kind of calling things this and that and that was okay, but I really wanted to see, so that the first year I was going for tea house was the same year I came up with some of the CBD material so I started putting CBD separately and realized that there were people at that point even really trying to find CBD and they were able to. So, that was great so I kind of took it on to be the CBD coordinator essentially and we try to, so I got some clones going from Lawrence and we handed those out to our cooperative, you know, as well as everybody’s seed growing wherever they wanted and again there wasn’t too much clone growing but we could be on the same page and there was some seed growing, we had some seed projects going. I think we had maybe six or seven people signed up to do some seed growing material out of what we knew to be high CBD seed from Lawrence. He was a member at that point, though he kind of closed the membership so a couple of years of that and then we did, we began to develop fair amount of IFC-6 at that point, 1:1, and I had some high 4:1 Cannatonic and then AC/DC and that was the highest at that time, highest CBD that we had and so most of the — there was no effort at really identifying this at the time, you know, it was just kind of word of mouth, but it was going through the TS collective and I just got more and more interested and the patients that were using it were actually finding these great responses to it for really serious medical conditions and three quarters of our people had, oh, I got a back ache, I got a script, wink wink and hey by the way can I get some extra pounds, you know, wait a minute, it was don’t ask, don’t’ tell, anyway. So, when TS Collective floundered because of difficulty of oversight with nobody was in – Distribution ended…it was complicated and we were kind of undercapitalized and stuff anyway and nobody quite knew how to approach this stuff and so by then I just started a new cooperative and by that point I had asked… Lost Coast Botanicals started – and that was Lawrence and me and Cath and then a couple of other people, _____0:32:48 and his partner and with the intention of only growing CBD material and then let’s see where this will go and then got huge, began to get real data, you know, about what was working for people and what wasn’t, it was fascinating because sometimes people would inadvertently get THC material, you know, it didn’t work, that wasn’t helping them. In fact, it was making them really distressed, you know, for these specific people, you know, that had been getting results and suddenly weren’t, okay, really, that’s information, you know, go back to it, fine. Other people couldn’t really tolerate CBD. They found it to be really, oh Samantha can’t take it, she and her partner they only used it for a couple of times, but still you know as they say, it feels like a coke high, you know, like coming down from a coke high they say. something but I guess, you know…

Dr. Corva: I know, right! (laughter) As a point of reference!

Christopher: Yeah, anyway. It’s wiry for them and that’s fine, you know, but absolutely having effects, you know, so really interesting and beyond whatever placebo effects may have and I am in favor of placebo effects. If you can create an effect, great, you know, and a lot of the pharmaceutical drugs actually operate on that…

Dr. Corva: I mean, that’s the effect or the placebo effect is that there is actually an effect.

Christopher: And that’s right, and the reason there is what is because you actually got your own system to respond and kick into doing what you’re supposed to do and then the — you’re cannabinoid system – you’re endocannabinoid system is an amazing thing and barely begun to investigate that and then with addictions and as an antidote to addiction that’s really an interesting aspect and then as an antidote to the other things that they give for dementia, those things and we have actually seen real effects and so as the caregivers, the nurses and home caregivers and everybody so this has actually been witnessed, you know, and the neatest thing about dementia patients is they’re like epileptic patients, the response is really vivid. They’re not there to, you know, oh, maybe I feel like, I don’t know whatever, you just see are they doing better or not, you know.

Dr. Corva: It’s pretty obvious, but there’s a bunch of patients that are being helped, right.

Christopher: Yes, the subjective step was really hard, you know, but you almost take out that whole placebo possibility when you see just direct results, you know, so.

Dr. Corva: I do want to talk to you more about like how you were able to get patients’ feedback; I mean obviously getting it up to dispensary doesn’t mean that patients are going to be tell you how effective you are.

Christopher: No. Well, that’s the difference of our cooperative basically is there is a lot of interaction.

Dr. Corva: Yeah. This is what I want to have you do a little bit more is talk about the Lost Coast Botanical model as it was, the difficulties with it as it developed as well, and also exactly the patient situation.

Christopher: Sure. Well, the real difficulty is that we can’t get the county to give us a business license and a brick and mortar dispensary, although the thing that’s about to change and that’s set us up for a whole complicated view because then we essentially have to be a delivery service and so forth and so on and do that in whatever way we can manage. So, that part has been complicated, but on the other hand we’ve been available by phone and we have tried very hard to develop relationships with practitioners so that they have a source for patients that they want to encourage to use CBD, which has been really hard to do and a quantified source. So, we went into this from an extractive point of view, we’re not looking at selling flowers so we wanted to be able to sell milligrams of CBD and THC in known values. So, just having that available was a big deal.

Dr. Corva: So, can you talk about the economic model whereby that was possible? You’re the extractor and dispenser and how is the product.

Christopher: Well, the way that that has been feasible is that we are a cooperative and not for profit mutual benefit cooperative like REI – so we don’t make a profit as a business. We don’t need to make a profit. If we were making a profit, we have to return it to the producing members, which is fine.

Dr. Corva: Producing members, that’s what I’m trying to get at.

Christopher: Okay, we have two tiers of membership. There are producing members and there are patient members and sometimes they’re the same because we encourage people to grow their own medicine and what we do is provide a number of phenotypes, six to seven different varieties at this point. I mean the first we had hundreds — well, not hundreds, we had about 24 and that’s just way too many and it got really complicated, but the point is we had enough people on the same page that we’d have a note there of small producers some only grow 6 plants – some people grow up 20 to 30. You know, the average really was around 12. We can count it all on the same strain, but that was enough if you have enough people doing it to make significant amounts, okay. Then, we would buy that material from our members at a set price and that…

Dr. Corva: But they knew about when they got the clones.

Christopher: They did know about, yeah, and we’re still holding that price at this point. It could change in response to the market changes, but it’s been really good. It’s really competitive. I mean I don’t mind saying what it is …

Dr. Corva: That’s not necessary information.

Christopher: Yeah, but the point is it’s at a price point where everybody was quite happy with it. It was better than they were actually receiving for high THC material that had to be manicured and graded. You know, we tested for being microbiologically clean and no pesticides and no, you know, that’s essentially what it is, but beyond that, all it has to be is all the trichome bearing parts of the plant. So, no stem essentially, but you know little flowers, you just strip it, it’s very easy to handle, you know, and cure it for…

Dr. Corva: It’s a lot less labor and it’s a lot less expense to actually produce.

Christopher: It is, although it turns out there’s something, you have to keep these batches separate from everything else. You think that would be easy, but hippies are hippies – it’s complicated but, you know, on the whole, everybody has been quite happy with that model, you know, and we’re moving towards full certification, but it’s been difficult to find who is going to do the certification and get it – so we’ve been self-monitored for way too long _____ certification who we decided to go with…

Dr. Corva: This is a huge part of the models, the actual sort of economic partner where like it’s sun grown and pesticide free.

Christopher: Well, that what always our model.

Dr. Corva: That is what patients should be getting.

Christopher: Yeah, exactly. And then beyond that we used to do ethanol extraction and CO2 extraction, but at this point we’re pretty much doing CO2 extraction. CO2 as compared to other extraction methods is the instruments themselves are expensive, but the operating costs aren’t too bad, CO2 is not expensive and we recycle, you know, we have a closed loop so it’s not like we’re just blowing it off, you know, and that but it kind of capture everything and concentrated really hard like BHO can or other solvents, petrochemical solvents, but it doesn’t leave any residue so all things considered it’s the cleanest thing we can come up with and we get pretty good yield. I mean we’ve been working on it. We can get, you know, about between 60 to as much as 85 grams return per pound, you know, which is good.

Dr. Corva: It’s about 12%, 14%, 12% to 14%.

Christopher: We hit the 14 to 17%. We have gone as high as 17.

Dr. Corva: Yeah, it’s excellent.

Christopher: Yeah, it’s not that we started it.

Dr. Corva: 10-12 is kind of a cut rate like baseline.

Christopher: I know, we started it between 10 to 12 and after getting more skilled with our equipment, we can now bring it in pretty close so we can count 14-15, you know, and that’s adequate, that’s fine, that’s a good enough against our price point, you know, for ____ so anyway but we’re just being for purely extractive material it really is, and then a limited number of, you know, phenotypes that we’re growing, it works pretty well, it’s a good model. So, as that becomes available, we have more and more people reaching out to us to get the material. The other thing is we’ve provided the material for a lot of people who are much better known than we are for product, you know, but it’s our product in those CBD elixirs, you know, so that’s fine, we’re happy to contribute to that. I just want to see more out there.

Dr. Corva: Yeah. Can you say some of the folks that might be carrying the product?

Christopher: Well, right at the moment, I don’t know if I’m supposed to, but I…

Dr. Corva: If you don’t know, don’t worry about it.

Christopher: It’s varied over time and you know a lot of people have taken the same model we’re doing and applied it and now they’re producing their own material. I can say _____0:43:14 because they wouldn’t have any problem with that _____ to say but, beyond that yeah, for the CBD material.

Dr. Corva: And so the primary way then that folks are, the patients take their medicine is through the vape pen is that correct?

Christopher: No, not really. I mean the vape pen is great. It’s a great way to get a quick infusion that will also dissipate pretty quickly too, but you can reach for it in the middle of the night, you can take it as needed. Yeah, it’s a great way to do it, but I would say only maybe a quarter of our serious patients really on a vape pen – we do capsules; we do 5 mg increments so you can titrate up or down. A big deal is not to get too much for a lot of people. And we do a tincture that’s 4 to 5 sprays equals 1 ml and then there are 5 mg per milliliter or 10 mg per milliliter. We do different…

Dr. Corva: Is that a decarboxylated tincture?

Christopher: It is, yeah, it has to be, decarboxylated, but that’s the nice thing about the vape pen, I mean it’s less fussy, but we do suppositories, tinctures and capsules and the capsules are just in coconut oil, which is you can’t let it go overheated, it’s a little fussy, we like to be able to put it in gel caps, but the machinery for that is really expensive and be lot more stable that way.

Dr. Corva: What about transdermal patches?

Christopher: We haven’t done that. People do, you know, it’s a possibility. You know, it absolutely is an option. We do a lot of topical stuff and to get a kind of transdermal effect. We did some experimentation with…but the problem is the carrier carries stuff in, so _____, but it carries everything along with it and it’s a really touchy kind of thing to use and so it really wasn’t comfortable offering that to patients. So, we’ll offer advice on how to do that for yourself if you want, but it’s a little touchy. It’s a great carrier though, but it will carry everything and you can have it carry stuff you don’t want.

Dr. Corva: Right, that’s the tricky part, right.

Christopher: I am really happy where we got to. Not transdermal, but I mean we did so much heavy lifting just to get to this point and way more than we really should have, you know, to stay viable, but because of this we worked really directly with patients. I mean we craft what patients ask for, I mean we make ratios specifically for what people feel they need or what their physicians tell them they need and so that’s been a big deal and because we’re accessible and because we go over great lengths to provide what people need we have a lot of data because people have really shared their stuff with us and we also work with the Society of Cannabis Clinicians – you know, those guys are really great and there is a module that they produce now that I think anybody that’s selling the stuff in dispensaries or purporting to offer medical cannabis ought to have taken that course at the very least, you know, really. I mean it should be mandatory, I mean to have some basic working information and it’s pretty good course, I mean really is, there’s a lot of big holes in it because real information is still not there – it’s scarce, but it’s got everything currently available pretty much on cancers, on PTSD, on epilepsy, dosage information, pediatric work, autism, not enough autism stuff, but some and the autism carries over to dementia because it seems like the same response is going on. There is a kind of spectrum of autism is now well, it’s been called an endocannabinoid deficiency syndrome because it’s been so linked to that response autoimmune response.

Dr. Corva: Yeah, Dr. Ethan Russo is doing research about that.

Christopher: Yeah, exactly, he’s got some new research that he is about to publish about that. Have you heard anything about that?

Dr. Corva: Not about his forthcoming necessarily, but he did give a talk actually just last month in Tacoma, it was an endocannabinoid deficiency talk so I assume that’s from the work he’s probably about to publish.

Christopher: Yeah, that and then the terpene stuff because he’s going to do that at the ICC thing and Halifax that so big deal.

Dr. Corva: Yeah, Michelle Sexton is going to be there too.

Christopher: Yeah, great. I wish I could be there….If I had the credentials….

Dr. Corva: Yeah, we’ll – we would give you some credentials, for sure…. In terms of like the data that you’re gathering, I’d like to just ask, you know…. One of the primary arguments against, you know, medical cannabis is the lack of research, which of course is totally man-made. (laughter)

Christopher: That’s why we do this on run I mean if it wasn’t illegal we wouldn’t have to do it this way. It would be obvious that will be fine, but it’s not obvious and yet people are suffering. So, we’re going to go ahead and do what we can, you know, until they absolutely tell us we can’t, you know, and they haven’t really told us that, you know, so..

Dr. Corva: What are the most promising areas for you given that you’ve seen — that you’ve lived this data.

Christopher: Yeah, palliative care in dementia. Those are the areas that I really want to concentrate on because I see that as the biggest potential for very clear and consistent results, yeah.

Dr. Corva: For the reasons we got into before. What’s it like working with older people who may be haven’t consumed cannabis before?

Christopher: It’s pretty great because there is nothing wrong with feeling good and once people get over that and acknowledge it, there are wonderful results, you know. It’s really astonishing how many people say, “God, I always thought this stuff was the demons thing – the devils dandruff – it’s terrible, it’s awful you know, oh God… but really it’s the only thing that helps me and thank you so much”… and I mean it’s like that over and over, you know, so what’s wrong with that, you know. I don’t see why… I don’t understand how it got that way… (laughter) But there it is…

Dr. Corva: It’s a long story, right?

Christopher: Yeah, it is as we know, but then the other really interesting thing is what has been kind of just submerged and left out of traditional cannabis using cultures that used to be really common knowledge and have now been suppressed out this whole deal, you know, like ayurvedic stuff that we’re talking about. How much of that was once well known and is now just kind of submerged under this notion that it must be bad, you know, so….

Dr. Corva: So, a scientific agenda can take cues from you know essentially lost knowledge.

Christopher: I think so.

Dr. Corva: That’s a rediscovery effort could be one way to go about it. What worries me is that, you know, the public discourse about creating more scientific knowledge as if it never existed before and doesn’t exist now and the effort to essentially bring in to the framework of modernity you know, essentially cannabis as a medicine, and modernity’s main problem seems to be its total rejection that anything came before it that was valid at all.

Christopher: Right. That’s too bad, you know, eventually, begrudgingly you have to admit that there were, hints that it must have been useful, you know, they usually tout out aspirin and a few other things as an example, but you know yeah that’s just unfortunate. The part that I find unfortunate is that there is a spiritual aspect to it that it really can’t address and that spiritual aspect is something that benefits our whole lives, not just our health. You know, our health is one manifestation of our physical, of our spiritual condition, you know, and sciences can’t bear that out, you know…

Dr. Corva: Yeah, they don’t have the tools to deal with that.

Christopher: They really don’t and it’s okay, you know, but it still is unfortunate.

Dr. Corva: It’s possible that, you know, radical psychologies somehow, the stuff in that direction.

Christopher: Well, it is because of the whole influence of the state of mindfulness and neuroplasticity in general, which is intimately linked to the endocannabinoid system is kind of now bringing into new possibilities that are quantifiable in some way that they can begin to go oh, well, there is a tangible something that we can look at, you know, but a lot of it is not going to remain, you can see the effects, but you can’t see how it’s generated and therefore it doesn’t exist, you know, and that sucks, you know, it’s so unfortunate that that’s the case.

Dr. Corva: Yeah. It comes from a misunderstanding of science itself. I think that the public somehow because of education system, because of commodification of knowledge, thinks about science as the decider of like everything that anything that can’t be verified by the scientific method is therefore not real and the whole point of scientific method actually is to deal with the unknown. If you don’t acknowledge that you can’t explain some things, then you can’t do science.

Christopher: Well, it’s also based on this model that everything is fixed and that you get the same reproducible results every time if conditions are same but conditions are never the same. The thing is everything does in fact change on an amazing level and until that’s acknowledged this moment is this moment, next moment will be that moment and the same things may not hold true and even in science you see this crazy bell curve deal where they can’t get reproducible thing with the same supposed conditions, but…

Dr. Corva: So, what is the acceptable range of variability? I think is also what the more sophisticated model.

Christopher: I know. It reaches out like that.

Dr. Corva: Is it start with a simple model and then like you introduce variables, but the thing is that like well, like the papers themselves they’re usually pretty good about acknowledging the limits of findings and what else needs to be done, the media around it never does like these are the results and like everybody this is your new truth now run with it … It’s very frustrating.

Christopher: I guess what I am trying to lead up to though is that there is I don’t see cannabis itself as being in itself, by itself this great panacea, I think there’s other factors that have to come into play with our, the way we see ourselves and our relationship to where we are.

Dr. Corva: And so this is a cultural thing that as cannabis enters the spheres of legitimacy, let’s say whether or not their legality is an issue. As as it does so, it becomes fetishized, it’s all about just cannabis and they’re for like, okay, we’re just going to…whereas like, you know, part of cannabis culture, if we can use that term, historically comes from a place of actually understanding how it’s part of a greater ecology or set of ecologies, essentially. And this, you know, I guess might be one reason why I have an interest in somehow carving out some space for an approach to cannabis that isn’t fetishizing it, but at the same time, you know, like – it’s difficult to know how do you balance that with actually sort of, you know, putting it aside and making it completely irrelevant and actually putting it in the greater context…

Christopher: But the culture itself, I mean is so in danger of being exploited for its you know – money gain and so forth capitalistic virtues – that’s a real problem too, it’s a real danger and – I mean I am not at all comfortable with a lot of the cannabis industry and the whole damn thing and you know the whole spin around it, it’s really unfortunate that it’s stuck in this corner and I’d like to see it broaden out into a whole other dialogue. Anything can be abused, I mean anything can be abused and cannabis is absolutely no exception and just to say, oh, whoopee – here we go and legalize it and things like that. I don’t like to see that either. I don’t like to that happen with booze and I don’t like to see it with flowers, you know. I mean if it was just flowers, that would probably be fine, but it’s not, you know.

Dr. Corva: And that’s, you know, the concentrate industry, it just happens approximately same period of time…

Christopher: Exactly and I mean – I was contributing to that just completely because, you know, these very things that we do can be used in all kinds of different ways, but the idea is – the smallest effective dose. That is what we are looking for here you know, and that it really should be true of almost any medicine and it turns out it almost can start operating like a homeopathic level, it’s not huge amounts necessarily with great results amazingly enough, you know. And in fact you get better results when you get a smaller amount than you’re doing a bigger amount, you know, in a lot of cases, but it’s not totally clear to me by any means. I wish it was, but it’s not, you know, how that works. So, you know, that’s my take of it.

AUDIO END

Video Produced by

Steve Hyde

Video produced for

Center for the Study of Cannabis and Social Policy
6701 Greenwood Ave N. Seattle WA. 98103 (2015)

References:
Lost Coast Botanicals tribute to Lawrence Ringo

O’Shaugnessey’s

State Building Code Leans Away from Smaller Rural Cannabis Farmers

by Dominic Corva, Executive Director
As a political geographer, I understand the core policy and market geography of I 502 cannabis to be shaped by the intersection of Public and Private Real Estate interests. Not WSLCB approval, not taxes, not medical access points, not legislative “fixes” for I 502. The main Public Real Estate interest at stake here is Land Use Governance, which is shaped by Zoning and Building Code rules and regulations.
The latest struggle for inclusionary I 502 policy in that regard is the Washington State’s Building Code Council’s efforts to impose F1 Industrial (ie, Urban Warehouse) building standards on I 502 production and processing that is now and will in the future primarily be Rural and Agricultural.
The first collective efforts to change this are emerging, not surprisingly, by I 502 producer and community organizer Crystal Oliver on the I 502 google group. She has posted her letter  to the Washington State Building Code Council on the group for others to adapt and send. Her fellow community organizer Jamie Curtismith has responded with complementary guidance in support of Crystal’s call.
I reproduce these letters below in support of “Agriculturalizing” Cannabis Policy in Washington State. It’s a great example of the need to consider Cannabis as Social Policy, in this case on behalf of the need for Agricultural rather than Industrial Land Governance.
by Crystal Oliver, Washington’s Finest Cannabis
Dear Washington State Building Code Council,
I am contacting you to voice my opposition of building code proposal IBC 15-035 and my disappointment that this proposal is being considered without a financial impact assessment being completed as it will adversely impact my small business.
My husband & I own and operate a legal WSLCB licensed marijuana farm in Spokane county. We presently grow our cannabis underneath the sun in the soil of our 10 acre farm.  We are coming up on our first year in business and are working busily in the field ourselves from sunrise to sunset hoping for a good harvest this fall so we can pay our mortgage, electricity, keep working for ourselves, provide a few jobs to others in Spokane county, and continue supporting our local community through our commitment to buying supplies and materials from other small local businesses. We had hoped to save up enough this year to install a few greenhouses next year purchased from a local supplier.
Proposal IBC 15-035 will have an extremely profound economic impact on my small business, other small businesses in the area, and quite possibly the future of this new industry and the potential tax revenues the State of Washington hopes to collect.
F1 building code requirements, require fire flow, fire flow generally requires the existence of a municipal water district.  My rural lot, surrounded by farms does not have access to a municipal water supply.
The green house operation that we are dreaming of is far simpler than the greenhouses of my fellow farmers down the road who raise leaf lettuce, tomatoes, and petunias who don’t abide by F1 building codes.  It is extremely unfair to apply more restrictive zoning to the production of marijuana than the production of other plants and vegetables.
This proposal also suggests that processing of marijuana sometimes involves the use of hazardous materials and lists this as reason to prevent farmers from operating on rural properties, however, Spokane County Building & Planning department, in cooperation with our County Commissioners came up with a solution to that.  They permit only limited processing outside Industrial areas.  There are no hazardous materials in use at my processing facility, I simply hand trim the cannabis flowers from my plants, separating the flower from leaf and stem and place them in bags and jars for sale at the retail store.  Spokane County allowed for limited processing to protect the small marijuana farmers in our county who are operating on rural properties.
This proposal, if adopted would prevent small, family farmers, in rural communities from being able to join, compete in, and thrive in this brand new and highly lucrative industry.
Over 20% of the marijuana producers and processors currently licensed by the WSLCB reside in Spokane County.  Many of us are on rural lots where we cannot meet F1 building standards.  A proposal that negatively impacts that large of a portion of this new industry will have a significant impact on sales and tax revenues collected by the state of Washington.
I urge you to decline this proposal as the economic impact that it will have on many small business owners in rural areas throughout the state is too significant to ignore.
Highest Regards,
Crystal Oliver
Managing Member
Washington’s Finest Cannabis

 

by Jamie Curtismith

F1 code compliance is yet another in a long line of strategies to get marijuana operations off rural lands. In Snohomish County, our building inspector (who also happens to be our Fire Marshall) had an ‘IBC interpretation’ that mandated operators to upgrade to these rigorous standards on non-public buildings, which industrializes otherwise straightforward agricultural-use buildings, making them truly manufacturing facilities (not agriculture) and therefore, not allowed in many rural zones. He claimed that his use of F1 had nothing to do with cannabis and more to do with building type, but his application of code became inconsistent and arbitrary as the industry came online and he began to realize the variety of barns, pole buildings, and rigid greenhouses being used.  Of course, the real problem is (other than the expense involved), is that several of the F1 requirements, as Crystal pointed out, are impossible to comply with (and therefore are a defacto ban) because many rural parcels lack the necessary services (power, water, emergency services…etc) to support “industrial use”. Some rural zones allow for manufacturing/industrial, for example, we have a rural light industrial (R1) zone where F1 Buildings would be acceptable, but it is only 0.00013% of the county (or 182 acres) and hasn’t had a parcel available for a few decades!

Caution: When arguing code compliance (IBC) try to avoid muddling the argument with zone compliance. From a building inspectors perspective, they don’t care (or have control over) where the industry is zoned. That is the responsibility of the Local Council. Inspectors only care about the types of buildings used for the purpose of the businesses operating in them. An inspectors job is pretty straight forward; inspect a building and apply IBC. One of the challenges that the marijuana industry has posed to building inspectors is our unrelenting creativity and resourcefulness. The facilities where some grow operations take place have been the most innovative utilizations that most inspectors have ever investigated (cargo containers, converted prefabs, MHUs, storage pods…etc) so there has been a tremendous amount of room for code interpretation around our usage. Not having been officially declared an agricultural crop (and awarded Right to Farm protections), we are viewed as manufacturing, so they are interpreting code accordingly (industrialization). That is why it is IMPERATIVE to get cannabis declared as an agricultural crop, which again, the state building council has nothing to do with, but it doesn’t hurt to keep arguing the ‘cannabis as an agricultural crop’ logic.

Also, many inspectors (and especially Fire Marshals) are still completely oblivious to our processing needs, and still have exploding butane canisters in their minds when they hear the words ‘cannabis extraction’. Most local municipalities have not figured out that processing-only licenses are not tiered, and not all will be extracting, but I don’t think that will stop reefer mad councils from implementing heavy handed measures on them.

Bottomline: This fight is happening on many fronts, among many regulatory authorities simultaneously, and we need all hands on deck to get Cannabis Sativa recognized as an agricultural commodity and get it regulated accordingly, so that ALL producer processors will be protected, not just small and rural growers.

 

Jamie Curtismith

206-491-3802

curti…@hotmail.com

Southern Humboldt’s Kerry Reynolds Recent Interview with Dr. Corva (With Transcript)

https://soundcloud.com/cannabisreport/cannabis-consciousness-21-dr-dominic-corva

 

by Dominic Corva, Executive Director

TRANSCRIPT BELOW

“Dr. Dominic Corva of the Seattle-based think tank Cannabis and Social Policy recently visited Southern Humboldt and talked with CCN’s Kerry Reynolds about lessons for California in legalization trends in Washington and Oregon.”

This is Cannabis Consciousness News produced at Redwood Community Radio in Redway, California.  I am Kerry Reynolds reporting for CCN.

 

Kerry: This is Kerry Reynolds with CCN.  I’m here with Dr.  Dominic Corva of the Cannabis and Social Policy Center, based in Seattle, Washington, correct?

 

Dominic: That’s correct.

 

Kerry: In terms of enforcement in cracking down on the black market, trying to pursued people into the above-the-ground market, are there any things you are seeing in Washington, in terms of cracking down more on the black market?

 

Dominic: So, you know, the black market needs to be defined, right?  We all assume we know sort of what the black market is but it’s also a term that gets used pejoratively to identify like mad people, as opposed to — the black market, you know, technically is, you know, the informal market essentially like un-taxed, un-regulated market.  So, the main thing you know in Washington that I suppose could be learned is that you really need to make sure that you’ve got plenty of retail outlets.  That is — you can have all of the best intentions and all the best designs for permitting growers but if their product doesn’t have a place to go, if there is a bottleneck because there is not enough retail stores then, you know, like you are looking at diversion from a, you know, regulated system.

 

Kerry: Yeah, then it’s going to be filled out at someone’s apartment.

 

Dominic: Yeah, so that’s — the distribution question needs to be worked out and whether that means necessarily like, you know, opening up retail permitting or coming up with farmer-to-consumer distribution, there are lot of different ways to I think create pathways to market from the field and California should consider all of them _____1:50 basically because it grows way more than California consumes and in that way it’s like Oregon, but on a much bigger scale, although I’m not sure how much bigger scale these days Oregon is.  There is a whole bunch of Californians in Oregon that are applying the lessons that they have learned.

 

Kerry: So, things are blowing up basically?

 

Dominic: Things are blowing up in Oregon.  You know, Oregon’s got the cheapest cannabis in the country now according to the latest map that came out of Cannabis Prices, and, you know, historically that’s the indicator of like, you know, where most of it’s coming from.  Of course, Oregon being right next to Northern California, it’s really — they should break it by county because it won’t be the whole state that will be cheaper.  It will be like, you know, that zone from the Bay area up to — that’s really, you know, a cannabis growing region that’s continuous.

 

In terms of certifying, you know, gardens as, you know, they have got their water permit and so forth, you know, the question is that, okay, let’s do that so that you know, we can get the environmental stewardship going, but on the other hand if you try to apply like a seed-to-sale tracking system in this area, you are throwing it all out the window because there is just too much products and it needs to go somewhere and they can’t all go into California, they just can’t; it’s not mathematically possible.  I think it should be interesting to see how that aspect of formalization happens in this area where, you know, attempts to shove people into a box that really like, you know, makes their lives too difficult and makes them not want to participate, gets kind of back to its first problem, which is like nobody wants participating from here because it doesn’t work with them.

 

So, there is going to be particularities to the area that’s going to be a little tough to work out in a nuance fashion at the state level, so I’m really hoping that — and it definitely seems to be the case the local government is much more interested in being involved in that.  Humboldt, you know, obviously had its head in the sand for a very long time just like everybody else.  I think that’s really, you know, one of the interesting things about Kevin using that all.  Kevin is like, that’s not head in the sand, that’s head out of the sand and actually looking around 360.  So, that’s promising to me.  It’s promising to me.  I think it’s easier to make sensible policy with people that like you’ve met face to face, you looked in the eye and you’ve talked to them and they talked to you.

 

Kerry: It was startling as someone who covers the industry here to see Representative Huffman, meeting with people that were out-cannabis farmers just recently and I believe Senator McGuire as well.

 

Dominic: Yeah, that’s right.

 

Kerry: So, to have Luke Bruner, representative of California Cannabis Voice Humboldt, sitting at the same panel table with the Lieutenant Governor was really showing how much the cannabis producing community has gained respect in order — and legitimacy in a way before the full legality has come onboard.

 

Dominic: Absolutely.  You know, I think that the politicians are responding to the organizing.  They understand it’s — Hezekiah, obviously, was also at that table.  Hezekiah Allen.

 

Kerry: Yes, in their early meeting.  I really think — and in a public meeting I was like, yeah.

 

Dominic: Went to public meeting, that’s right.

 

Kerry: But Hezekiah Allen of Emerald Growers Association, also representing cannabis farmer.

 

Dominic: They are at the table and like that’s the first step.  It is like sitting down at the same table.

 

Kerry: And even John Corbett, the Chair of the North Coast Regional Water Quality Board sat at that meeting.  When we go to do our water inspections, we don’t check for 215s and we don’t care if it’s medical cannabis or just cannabis.  So, there is sort of our recognition of reality on…

 

Dominic: There is progress — there is real progress being made; just so much progress being made on dealing with what is actually there instead of what you wish was there or not there.  You asked me about, you know, lessons from Washington and Oregon.  Did you want to, you know, talk about the elephant in the room which is the tendency that Oregon has at least now kind of confirmed for legal cannabis to be an occasion to radically change, you know, essentially medical cannabis?

 

Kerry: Are the dispensaries of California going to go the same way as the dispensaries in Washington and by the way, what’s happening with the dispensaries in Washington?

 

Dominic: Yeah.  So, basically what’s happening with dispensaries in Washington is there is Senate bill they just passed 505(2), that was essentially sort of a comprehensive medical marijuana, you know, regulation act and if you will recall back in 2011 we had one of those.  And it established a system for, you know, regulating commercial, you know, medical dispensaries and our governor section vetoed every part of it that had to do with regulation.

 

Kerry: The Washington Governor.

 

Dominic: Washington Governor basically because any part that would have involved a government official like, you know, being a part of that regulatory process — what she said then was, subject to them to Federal prosecution and so section vetoed out, you know, every part of it that would have been regulation.  And so all the folks who were geared up to, you know, satisfy the regulatory conditions in that bill which came from legislature and not initiative, they know what to do and so they got the legal advice that pretty much became standard practice which was, to operate as collective gardens and there was collective garden language and of course, collective gardens in that bill did not have to be regulated.  They were non-commercial provisions.  They were appendages to the actual regulatory structure which involved commercial regulation.

 

So, what we have is essentially excess point system that was — that sprang up not overnight at all, but certainly under the new conditions basically, if you’re a collective garden them you weren’t regulated, so it’s really easy to open up.  All you got to do is find a spot in the strip mall.  That’s the — that was the legal interpretation that they were operating under for four years and until the cannabis decision from last year, which was the first like — sort of challenged, that actually was ironically brought by medical cannabis activists to essentially get a legal opinion that, in fact, excess points were legal in the State of Washington and of course, they got the opposite result.  And since then basically like all anyone has had to do was apply that decision wherever they were and if they want to, you know, basically declare medical marijuana illegal, and that’s essentially what happened.

 

So, with 505(2), it creates a medical aspect to the legal cannabis markets.  I don’t want to go too deep into those.  I think we have talked about that a lot before, but what’s happened to the existing dispensaries is that City of Seattle is now kind of leading the way in terms of a specific framework for it, because technically everybody’s got till July of 2016 to be open.  City of Seattle issued essentially a three-tiered process for dealing with all of the dispensaries within its jurisdiction.  So, the first tier is essentially, if you opened up your dispensary after January 1st, 2013, you are out.  So, you are regarded as a, you know, as an opportunist.  You are just showing your lack of good faith because you opened up after legal cannabis passed.  So, that’s a condition.

 

The second condition and that’s one — this one was unanticipated I think and a little bit surprising to folks, is that the laws for legal cannabis which are only for people 21 and over, just got applied to dispensaries.  So, dispensaries basically were now being investigated every time they sold to a patient that was under the age of 21; that’s ongoing.  And so as a result the dispensaries and dispensary system — any patient that they had that was under 21 which, let’s say, was a fair amount actually — a lot of their clients are…

 

Kerry: Children with epilepsy, for example.

 

Dominic: Yes.  But children with epilepsy were not coming and buying, you know, _____9:50 on a regular basis necessarily at the dispensaries.  But there is a current way in which actually people under the age of 21 can go to a dispensary and wouldn’t get the dispensary in trouble and that’s if they got essentially like a caregiver letter.  Now, under the new system basically which, you know, again it will take a while to kind of implement it, instead of collective gardens there are four-person cooperatives that you can register with the State, and I think it’s three plants per person so, like you know four times three is twelve.

 

So, the new legality is, you know, one that is radically different from what was going on already, which makes it a pragmatic policy because what it’s doing is actually not really like working with what’s there and trying to shift it, it’s denying what’s there and burying your head in the sand and just saying, just go back to the black market basically.  So, that’s the interesting dynamic that’s going on right now and Washington’s dispensaries even if they are not shutdown because they are all getting letters in there — if they don’t shut down then they get like a huge fine and the other conditions are they have to be, you know, paid up on their taxes.

 

Kerry: How many dispensaries are we talking about here in Washington who are now illegal and being told to shut down because of this…

 

Dominic: Well, they are being told not necessarily to shut down unless they have — they meet their prior conditions already like you say — again, if they have not been paying their taxes, there is your letter you should shut down.  You have been paying their taxes, you were open before January.2013, we are going to leave you alone and also you now get to apply to be part of the rec system.  And let me say that the mathematics of this are not as severe as you would expect.  The City of Seattle counted something like a 106 dispensaries within its city limits and identified that about half of them actually have been open before January 1st, 2013.  So, like for their first cut half of them were still surviving as eligible to continue as part of the system.  Now, of course, then they are going to have to meet, you know, the zoning requirements and all the other things.

 

So, like how many of those people actually end up in the rec system, not sure, but again this is the good actor, bad actor, you know, a discourse.  It’s like let’s identify the good actors and then _____11:55.  Everyone else is a bad actor and has to go away except for that’s not how it’s ever worked within the context because really more people will just go away, they find other ways to do business.  So, what’s happening essentially is our, you know, not terribly regulated medical system in Washington is being actively downsized and dramatically changed.

 

Kerry: And at the same time production is increasing.

 

Dominic: Yeah, so the production side of things — of course, the rec side of things especially that’s an issue because Washington has never been obviously a big producing State.  It’s been, you know, an indoor producing State and importer of you know Oregon, BC and California cannabis.  But with the 502 system of course like that’s a native production, you know, system and that system we are getting up to about 800 pounds a month indoor basically.  It seems to be moving through the inventory.  Our outdoor season last year on a very abbreviated one again, you know, 14,000 pounds and created within the i-502 market, you know, a gloat and a problem with prices and so forth because we had 80 retail stores open in December.  We have like a 150 open now.  We are on schedule to have about 250 open in December of this year.

 

So, not even the full component of 335 that like the state has authorized there to be for a number of reasons, bans, inventory and so forth.  But what that says to me is that you got twice as many retail stores.  Let’s be generous and call that three times as many retail stores.  You are going to have at least 10 times the production.  So, what does that say for, you know, the outlets and the prospects of, you know, diversion or of folks who may even be actual growers who are growing buds but are not able to sell their stuff because there is not enough retail outlets essentially for it.  It’s a chokepoint.

 

So, this is all happening of course in the context of downsizing the medical dispensaries and so fewer medical dispensaries, not enough retail dispensaries, lots of production on legal side, plenty of production around in Washington State, I mean that’s legal side.  All that is recipe for, you know, what the state says it doesn’t want which is diversion in the black market.

 

Kerry: And it’s what the Department of Justice says, it doesn’t want through the Cole Memo.

 

Dominic: But that’s the funny thing about the Cole Memo.  The Cole Memo is actually relatively broad or vague and when it comes to talking about diversion and the conditions under which the legal experiment can go forward which is — which folks interpreted additionally, diversion meant out of the legal market into any other part, whether that meant out of the state, in the state.  If it was produced in the legal market, it needed to be sold in the legal market.

 

So, diversion was interpreted as being just about legal cannabis.  Since then diversion has been now applied to include essentially medical cannabis and so, medical cannabis is considered to be, you know, black market or diverted.  You know, if you don’t have a system regulation, it’s all diversion.  Diversion is the condition of not regulation according to the sort of latest popular sort of interpretation, which is why, you know, part of the justification for shutting down medical system is because Cole Memo.  And the Cole Memo, again, originally like did not at all apply to medical.  Why would you ask the states to be home to a standard that the Federal Government has never been able to actually keep itself, which is shutting down the black market.

 

If we interpret the Cole Memo to include that kind of demand, what we are doing is essentially saying the Cole Memo, you know, is absurd on its face and, you know, like how we are supposed to take it seriously at all.  If it sets an impossible condition and you are interpreting that impossible condition as something you have to meet even though you can’t, it would be totally impossible and you don’t have the funding to do it, it’s taking steps backward Kerry.  So, for me that’s a concern in Washington State.

 

It’s not like I’m here to defend, you know, unregulated or deregulated cannabis; I’m for regulated cannabis.  I’m for evidence-based regulation though.  You know, evidence that this works and that by the way is also part of the Cole Memo.  It has to actually work.  That’s a condition.

 

Kerry: Robust regulation.

 

Dominic: Robust regulation, which is interpreted as regulation that actually like does what it’s supposed to do and that’s not a reinterpretation of the Cole Memo.  That’s an original interpretation of the Cole Memo and it still applies and I believe that, you know, our legislature has fallen down you know, on their faces when they are ignoring — they are ignoring that part of the Cole Memo.  Cole Memo says it’s got work.  They are doing stuff that’s the opposite essentially and I feel like…

 

Kerry: Probably not their intention to do it.

 

Dominic: Yeah, probably not.

 

Kerry: So, we have got a long — we have got a lot of issues in Washington and I think you have given us a real good overview of that.  I know you have also been doing more analysis of the Oregon recreational market.  What’s the status today in Oregon, please?

 

Dominic: Well, what’s happening in Oregon is that’s — although Oregon had a regulatory system, you know, the Oregon Medical Marijuana Act, they were cruising along after initiative passed, there was a joint taskforce, you know, bipartisan, you know, both members of the _____17:14, and what they were tasked to do is writing rules to create the legal market and it had nothing to do with medical, nothing.  Somewhere along the way that joint taskforce essentially stumbled over, I think increasingly like the fact that it wasn’t addressing medical and essentially dissolved and we are left now, instead of the joint taskforce that actually has been listening and trying to figure things out, we are now seeing in Oregon the position of an agenda that looks a lot like Washington’s.  It’s an agenda that claims that Oregon needs to be concerned about the Cole Memo’s diversion situation.  Again, the diversion thing is really — it’s getting hammered home as a common sense discourse and is being redefined in my opinion.

 

Kerry: By whom? Who is doing this?

 

Dominic: Well — so, you know, it’s usually hard to tell but you know we do have a white paper that was produced by a Privateer Holdings Incorporated, same folks who own Leafly.  They are an investment group.  They are based out of Seattle.  They have run Tilray, a big cannabis warehouse in British Columbia and, you know, they are essentially venture capital firm that invests, you know, in and around the cannabis industry.  Now, what this really means right now is that, you know, they invest in real estate, they invest in things like Leafly, you know, really safe things or you know what…

 

Kerry: Things that are directly touching…

 

Dominic: Right.

 

Kerry: The plan, the dangerous plan.

 

Dominic: Yeah, except in Canada, right Tilray.

 

Kerry: Okay, and that’s a producer and seller.

 

Dominic: So, Tilray is a production facility, so — exactly.  So, like they want to get into that.  They think very highly of their ability to do so and they think essentially — obviously, what works for the Canadian system is, you know, the fact that it’s a centralized sort of warehouse production predominant system.  And that is not the system that works on the West Coast United States because to do that — even if they were able to capture the market that they think they can capture, we don’t need more people growing cannabis here on the West Coast.  We have got a lot of people who have been doing it for a while and doing it pretty well.  Freezing those people out of the legal regulated market basically by, you know, making it harder and harder for them to meet conditions to be in it, which is — the white paper is very much, you know, there’s a very explicit like a medical market needs to be reigned in and, you know, legal market needs to be _____19:40 them, right said.  Centralized warehouse production and so it’s a white paper, right.  So, that means it’s for policy makers and it’s like this is your issue in Oregon and this is — but it’s very…

 

Kerry: But it’s being written by someone it sounds like or an entity that has a very obvious agenda.

 

Dominic: It has a private interest.  Yeah, it’s a really-really naked agenda, you know, like it’s not even pretending.  They are basically saying — there is a certain kind of attitude there that’s — it’s a little incomprehensible to me.  But that’s public documents and it was meant to guide policy makers and very recently, you know, that’s the direction Oregon policy is going which is to remove protections from medical cannabis growers that currently exist for them, and that’s the key thing.

 

So, for Oregon — like California, Oregon is a big exporter.  You know, Oregon system — the concept of diversion like has to be treated very pragmatically because you cannot mathematically fit Oregon production into an Oregon consumption system.  It’s not possible.  What you do with everybody else there…

 

Kerry: Well, come on doctor, if everybody started smoking pot from morning to night maybe.

 

Dominic: I’m not sure actually.  Like — possibly, I don’t know, but certainly…

 

Kerry: Yeah.  Okay, so Oregon is also an exporter?

 

Dominic: Also, a huge export — so, the question is in terms of the social ecology is that, okay, they are producing a lot of cannabis and they have been doing under the legal protection of Medical Marijuana Act.  So, they get X amount of plants and they grow outdoor plants in Southern Oregon and they grow big ones, right.  So, the problem is that the protections are being talked about as that’s what they need to take away.  So, that would leave these folks without a pathway into the rec system, (a) because they can’t fit into it and (b) kind of leaves them back in the space of vulnerability that they haven’t, you know, had to — they have been able to be integrated members of society in many ways obviously because they have been left alone.

 

Kerry: So, the celebrated legalization of cannabis in Oregon is now making medical growers in Oregon more illegal.

 

Dominic: It is — vulnerable, that’s right, yeah.  That’s the trajectory right now.  It could change next week.

 

Kerry: So, who would they expect to grow the cannabis in Oregon?

 

Dominic: Privateer and — Privateer Holdings Incorporated perhaps.  Who do they expect to grow?  The people who get in on the system basically, who are able to get into the rec system.  Again, like those rules are still being sort of written, they are still being hammered out.

 

Kerry: So, there are no licenses now yet, it’s still in process; sounds like it’s getting pretty butchered from the original voter concept.

 

Dominic: Absolutely…

 

Kerry: Spirit of the law.

 

Dominic: I’m sure that that is the case and so for me it’s very interesting to watch this sort of medical cannabis versus legal cannabis like antagonism develop because it’s framed in a one way and it can’t be framed another.  It’s framed as, you know, these people are not worthy citizens because they are all gaming the system anyway.  Medical marijuana is a fraud, is the discourse, right and that’s why essentially these things are happening in Washington and Oregon because policy makers have been convinced by someone or someone’s such as Privateer Holdings that medical marijuana is a fraud.

 

Now, what I understand obviously, you know, all cannabis, especially medical like _____22:56, but on the other hand I understand that _____23:00 doesn’t really fly necessarily to the American public.  What I would say, you know, to the American public is that actually, you know, medical marijuana laws are not just about the right to health and therefore about whoever is being fraudulent about claiming that right to do things to make money for example.

 

It’s also about legal protection from an insane drug war and especially for growers that is the case.  Why is it that like — it’s not okay for folks to grow, you know, herbs in their backyard, why is it that we have to track this like it’s nuclear waste instead of an herb.  Why is it criminal to grow a plant and to me like — medical marijuana instead of fraudulent I would say that it has been a shield and I think it’s been human right shield for, you know, a more ecologically, you know, in-tune population essentially to carryout direct civil disobedience against an unfair, unjust, racist and genocidal law.  The threat to our society has come from the drug war not from, you know, people growing plants.

 

Kerry: And in the meantime, these people that they are —

 

Dominic: They need those protections, they need to keep them.

 

Kerry: They have also been providing the medicine that has been saving children with epilepsy from 200 seizures a day, etc., so that sort of recognition we saw in Garberville because of the organizing in education that’s been done by the grower population here in Northern California.  That’s not coalescing as well in Oregon yet, and would have to pretty quickly to reverse this trend would you say?

 

Dominic: Well, you know, to be honest Oregon is incredibly organized and, you know, they have had _____24:35 in the room like I spoke to the Oregon Sun Growers Guild, you know, last year when they were like, you know, what do we have to expect coming up, you know, I was talking about well, this is the rule making process and Jonathan Mann was in the room _____24:45 and he was like, and this is how it’s going to work in Oregon, you know.  He gave the very specific thing.  So, they have been there.  They have been in the room.  They are talking to each other in a way that never was the case in Washington and still this is happening and that’s what scary about it, is that, this is not, you know, defenses population that’s been mobilized against; these were activated citizens who were already calling their, you know, representatives and being very engaged in the process and they are still getting shoved out.

 

So, it’s difficult to say, you know, like — obviously, I don’t have the answer for you know, how it’s going to be reversed.  I’m hoping that by presenting, you know, evidence in the base policy recommendations that I’m hoping that that can help; it didn’t help in Washington, so I don’t know.  But, you know, either way the upstart of this is the whole thing is going to move forward one way or the other and it’s either going to be moving forward with, you know, more social antagonism because of the policy that’s been created is going to be less.  Either way we are going to have legal cannabis and we are going to have medical cannabis and one shape or form we will have a black market, but the fact is that people are making decisions that are changing the landscape in a way that is potentially, you know, productive of more conflict in society rather than less and that’s my main concern.

Kerry: Thank you for all the work you are doing with Cannabis and Social Policy in Stanford.

 

Dominic: Thanking you for getting the word out.

 

Kerry: Cannabisandsocialpolicy.org, correct.  Any closing remarks?

 

Dominic: Yeah, I do actually want to, I want to give a plug for the women’s groups that are starting to proliferate here in Humboldt, CCVH Women’s Group and the Women Grow.  There are meetings that happen in Northern Humboldt, meetings happen in Southern Humboldt.  This is — honestly, if there is anything I can tell you about Washington that’s really positive is the women’s groups have been, you know, incredible.

 

Kerry: In Washington?

 

Dominic: Yeah, they have been, you know, powerful and humane and forces of good and I see that happening here too and I’m really starting…

 

Kerry: Yeah, Normal Women’s Alliance also.  So, we have three different, four different women groups that are really gaining momentum here in the region which is also very promising.

 

Dominic: I’m really excited about that.  I think they will make the difference honestly.

 

Kerry: Yeah, bringing women to the table always helps the discussion.

 

Dominic: Yeah, absolutely.

 

Kerry: All right.  Well, thanks Dr.  Dominic Corva.

 

Dominic: Thanks Kerry.

 

Kerry: Okay.

 

That’s all for today’s show.  Thanks for listening and join me again next week 5:30 p.m. for another special edition of Cannabis Consciousness News.  You can also find links to this and past programs on the Facebook page Cannabis Consciousness.  Reporting from the heart of the emerald triangle, this is Kerry Reynolds.

Inventory Stories June 2015

Inventory June 15 final

Chart by Dominic Corva, using data from”Weekly Marijuana Report” http://www.liq.wa.gov/records/frequently-requested-lists, accessed 6/18/2015

By Dr. Dominic Corva, Executive Director

Late Spring 2015 has come and gone. While wholesale prices have stabilized relative to Winter’s crash, Washington’s legal cannabis market exhibited zero evidence of a market clearance that usually leads to more favorable wholesale prices in late spring and early summer. We clearly have more than enough cannabis to serve approximately 150 open I 502 recreational stores, and that does not bode well for I 502 producers for Fall 2015.

The chart above was created by using the WSLCB June 17, 2015 “Weekly Marijuana Report,” in which Usable Marijuana Sales are subtracted from Usable Marijuana Production on a monthly basis to show an accumulated inventory of 6,293 lbs, about a month and a half of supply at the current 4000+ lbs per month sales rate. This is actually a “processing” inventory, not a production inventory, so we don’t really know — nor can we know, as far as I can tell — what the production inventory might be. On the same weekly report, “Marijuana Flower Harvested” does not equate with “Usable Marijuana,” as the former is a raw production number and the latter is what ultimately gets packaged out of said harvest. Producer inventory can and does sit in storage until it is packaged — “processed” — for the wholesale market, which usually only happens when a processor thinks they can sell it.

So the chart above represents the difference between when a processor thinks they can sell it, and when they actually do. And of course usable marijuana can be turned onto all sorts of processed goods, not just flower. Here is the WSLCB harvest chart, reproduced below:

Marijuana Flower Harvested

 

The chart above gives us raw numbers, which we need to qualitatively assess as “indoor”; “light dep”; and “outdoor” in order to get a sense of what’s going to happen later this year. Indoor production occurs year round; light dep is a type of outdoor usually harvested June-August; and “outdoor” refers to full-term outdoor harvested September-November (the “November” part really refers to when we manage to count October’s harvest). I’ve created a table below for consideration.

Pounds Harvested Type of Harvest
July 352 Indoor likely
August 1014 Light Dep and Indoor
September 1907 Light Dep
October 7172 Mostly Outdoor
November 13702 Mostly Outdoor
December 4051 Indoor likely
January 4016 Indoor likely
February 3515 Minimum indoor capacity
March 5117 Indoor likely
April 5420 Indoor likely
May 6426 Indoor likely

 

As you can see, indoor production has been surging this year and now seems to represent about 5,000/month. There’s plenty more to come, but note that about half of last November’s supply shock from outdoor is being produced on a monthly basis. By November we could have 1.5X that much, or 7500 lbs/month.

The question is, what’s November 2015’s outdoor harvest going to look like? Remember last year, about half that production came from SIX Tier 3 outdoor producers (plus ONE Tier 2 indoor), out of 185 “active” producers at that time. We have 404 producer/processors licensed right now, and we expect about 30 of those to be Indoor Tier 3s; 44 to be “Both” indoor and outdoor Tier 3s, and about 47 of those to be “outdoor” Tier 3s, using WSLCB information provided to CASP to create sample percentages for the industry for 160 I-502 producers.

That’s about twice as many licensed Tier 3 outdoor producers as there were last November, and of course it doesn’t take into account Tier 2 outdoor production (Tier 1 outdoor barely exists). Further, that’s the number of outdoor producers who are potentially able to grow all year, including light dep production. Light dep canopy does eat into full-term canopy projections — how much, I have no idea at the moment. But compare with last year’s cohort, which began in mid-lat July as opposed to April.

Let’s get back to simple math. At this rate, it’s not unreasonable to project indoor harvest capacity in November between 7000-8000 lbs. Let’s conservatively project outdoor production capacity at least three times the capacity as last year, but probably more like 5X-7X last year’s capacity (note that indoor production is up at least 10X from July 2014, right now). That’s 39,000 lbs. of outdoor, and 7500 lbs of indoor, for a November harvest of about 46,500 lbs.

Then, add the inventory that was accumulated over the previous 12 months. Currently, 6,293 lbs, or a month and half supply at current retail movement.

Add light dep to the picture. Consider the degree to which light dep production will happen in the next three months — we should have a better idea of what that means next month, when the first light dep data should become evident.

Add to that the unknown quantity of “Marijuana Flower Harvested” but not produced — from last year, light dep, and indoor.

What can we project? I could pull numbers out of thin air all day long but I prefer not to do so in this forum. We can, however, be qualitatively certain that there will be a harvest tsunami that will leave many producers — if not most — with Serious Inventory Problems.

Many, if not most, will go out of business. It’s not like the industry has lots of capital to tide it over till it can be sold — in fact, post-tax season, most producers and producer/processors struggle to stay afloat now. While concerns about how much of the I 502 industry will go under can be thought about as a “private” concern, here’s a public one: if you are a producer sitting on several hundred pounds of cannabis you can’t sell, and you decide to liquidate, it’s going to be awful tempting to liquidate outside the legal market.

There’s plenty we still don’t know, and lots of information yet to come in. Let’s see if the WSLCB moves quickly to license existing medical retailers with “medical endorsements” — there are about 400 of those in the state, and maybe half of them could convert very rapidly into I-502 retail points. That would help considerably. It would also help considerably if the WSLCB could open up the remaining 160 or so retail lottery winners, but a significant chunk of those simply can’t open because of local jurisdictional bans. And what about the retail applicants that didn’t win the lottery? Many of those are current medical access points, so that would help. But many of those are not going to be happy to get jumped in line by medical access points that were not in the lottery.

The solution is simple, of course — open up the rest of the retail applicant pool to all lottery applicants; and also move to convert as many existing medical access points as possible as can into the I 502 retail system with “medical endorsements,” as must happen anyway.

 

I 502 Industry Tips Away From Producers, Processers

Percent of Revenue from Wholesale - May2015

 

by Dr. Dominic Corva, Executive Director, and Dr. Jim MacRae, Research Associate

The I 502 cannabis market is just shy of its first birthday, and this chart demonstrates the consolidation of gross revenue at the retail level over the first 11 months. The first three months of the story took place when a few dozen retail stores struggled to stay open and stocked with cannabis. This condition was alleviated considerably as the first light dep crops were harvested and processed through the system: producers and processors continued to command premium wholesale prices through November. But on November 15, 2014, Randy Williams of Fireweed Farms put up his entire outdoor harvest for auction, netting about $2K per pound wholesale, or roughly $4/g.

Wholesale prices plummeted over the next month and have stayed low ever since, although there has clearly been price stabilization starting in February that indicates the fall harvest inventory began clearing. Some of the wholesale price pressure has been alleviated by the opening of new retail stores. At last count, 148 out of 163 approved retailers have reported sales and thus should be considered operational. At the same time, however, indoor production is coming online rapidly: May’s harvest numbers from the WSLCB came in at 6494 lbs. This includes both bud and raw material for processing into extracts and edibles, but note that this figure is about half that of last November when the outdoor harvest sent wholesale prices tumbling to a range of $2-$7/g.

Thus the story of the chart, in which retailers are capturing a larger and larger share of industry sales. On the one hand, this is visual evidence for the logic of collecting I 502 taxes at the point of retail, a legislative I 502 fix that is currently stalled in special session after special session. Until this fix arrives, wholesalers — and to a lesser extent, processors — will be squeezed tighter and tighter between the rock of plentiful supply and the hard place of exorbitant excise taxes. In between, the excruciatingly slow expansion of retail concentrates industry sales revenue at the end of the supply chain.